open access

Ahead of Print
Research paper
Published online: 2021-06-17
Get Citation

The struggle against endometrial cancer: ten years of experience of a tertiary center

Ahmet Bilgi1, Abdül Hamid Guler1, Mehmet Kulhan1, Ersin Cintesun1, Metecan Ates1, Cetin Celik1
DOI: 10.5603/GP.a2021.0138
·
Pubmed: 34155618
Affiliations
  1. Department of Obstetrics and Gynecology, Selcuk University Medicine Faculty, Selçuklu, Konya, Turkey

open access

Ahead of Print
ORIGINAL PAPERS Gynecology
Published online: 2021-06-17

Abstract

Objectives: We aimed to investigate the clinical and pathological factors of our patients who were diagnosed with endometrial cancer in terms of prognosis. With this study, we present our 10 years of surgical experience in endometrial carcinoma cases.

Material and methods: Four hundred twelve patients with endometrial carcinoma who applied to our center between 2010–2019 and that we followed up were evaluated retrospectively.

Results: Most of the tumors were low-grade endometrioid malignancies. Non-endometrioid types accounted for 12.1% of cases. Lymph node dissection was performed in 395 of 412 patients (95.9%). 66 (16.01%) of the 412 patients died during the follow-up period in the study sample. Higher OS and DFS rates were associated with endometrioid histological types, FIGO stage, absence of lymphovascular space invasion, lower grade and less than 50% myometrial invasion (p < 0.05). 5-year OS at stage 1, 2, 3, 4 was found as 88.9 ± 2.2%, 65.5 ± 10.8%, 49.4 ± 0.79% and 23.7 ± 0.97% respectively. 5-year DFS at stage 1, 2, 3, 4 was found as 84.1 ± 2.6%, 65.5 ± 10.8%, 47.7 ± 0.78% and 23.7 ± 0.97% respectively.  In univariate analysis, Age, tumor histology, FIGO stage, histological grade, LVSI, positive peritoneal cytology, cervical involvement, myometrial invasion and not receiving adjuvant therapy were defined as prognostic factors.

Conclusions: Age, grade, FIGO stage, myometrial invasion, histological type, LVSI involvement, cervical involvemet, positive peritoneal cytology and not receiving adjuvant therapy are important prognostic factors for progression-free survival and overall survival in patients diagnosed with endometrial cancer.

Abstract

Objectives: We aimed to investigate the clinical and pathological factors of our patients who were diagnosed with endometrial cancer in terms of prognosis. With this study, we present our 10 years of surgical experience in endometrial carcinoma cases.

Material and methods: Four hundred twelve patients with endometrial carcinoma who applied to our center between 2010–2019 and that we followed up were evaluated retrospectively.

Results: Most of the tumors were low-grade endometrioid malignancies. Non-endometrioid types accounted for 12.1% of cases. Lymph node dissection was performed in 395 of 412 patients (95.9%). 66 (16.01%) of the 412 patients died during the follow-up period in the study sample. Higher OS and DFS rates were associated with endometrioid histological types, FIGO stage, absence of lymphovascular space invasion, lower grade and less than 50% myometrial invasion (p < 0.05). 5-year OS at stage 1, 2, 3, 4 was found as 88.9 ± 2.2%, 65.5 ± 10.8%, 49.4 ± 0.79% and 23.7 ± 0.97% respectively. 5-year DFS at stage 1, 2, 3, 4 was found as 84.1 ± 2.6%, 65.5 ± 10.8%, 47.7 ± 0.78% and 23.7 ± 0.97% respectively.  In univariate analysis, Age, tumor histology, FIGO stage, histological grade, LVSI, positive peritoneal cytology, cervical involvement, myometrial invasion and not receiving adjuvant therapy were defined as prognostic factors.

Conclusions: Age, grade, FIGO stage, myometrial invasion, histological type, LVSI involvement, cervical involvemet, positive peritoneal cytology and not receiving adjuvant therapy are important prognostic factors for progression-free survival and overall survival in patients diagnosed with endometrial cancer.

Get Citation

Keywords

endometrial carcinoma; lymph node; stage; prognostic factors

About this article
Title

The struggle against endometrial cancer: ten years of experience of a tertiary center

Journal

Ginekologia Polska

Issue

Ahead of Print

Article type

Research paper

Published online

2021-06-17

DOI

10.5603/GP.a2021.0138

Pubmed

34155618

Keywords

endometrial carcinoma
lymph node
stage
prognostic factors

Authors

Ahmet Bilgi
Abdül Hamid Guler
Mehmet Kulhan
Ersin Cintesun
Metecan Ates
Cetin Celik

References (23)
  1. Lortet-Tieulent J, Ferlay J, Bray F, et al. International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018; 110(4): 354–361.
  2. Gultekin M, Kucukyildiz I, Karaca MZ, et al. Trends of gynecological cancers in Turkey: toward Europe or Asia? Int J Gynecol Cancer. 2017; 27(7): 1525–1533.
  3. Teter Z, Śliwczyński A, Brzozowska M, et al. The assessment of overall survival (OS) after adjuvant chemotherapy for patients with malignant endometrial cancer in Poland. Ginekol Pol. 2017; 88(6): 296–301.
  4. Cote ML, Ruterbusch JJ, Olson SH, et al. The growing burden of endometrial cancer: A major racial disparity affecting black women. Cancer Epidemiol Biomarkers Prev. 2015; 24(9): 1407–1415.
  5. Sawicki S, Kobierski J, Liro M, et al. Micrometastases in sentinel lymph node in endometrial cancer patients. Ginekol Pol. 2015; 86(4): 262–267.
  6. American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol. 2005; 106(2): 413–425.
  7. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000; 355(9213): 1404–1411.
  8. Wu Y, Sun W, Liu X, et al. Age at menopause and risk of developing endometrial cancer: A meta-analysis. Biomed Res Int. 2019; 2019: 8584130.
  9. Ayhan A, Taskiran C, Celik C, et al. Surgical stage III endometrial cancer: analysis of treatment outcomes, prognostic factors and failure patterns. Eur J Gynaecol Oncol. 2002; 23(6): 553–556.
  10. van Wijk FH, van der Burg MEL, Burger CW, et al. Management of surgical stage III and IV endometrioid endometrial carcinoma: an overview. Int J Gynecol Cancer. 2009; 19(3): 431–446.
  11. Mariani A, Webb MJ, Galli L, et al. Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol. 2000; 76(3): 348–356.
  12. Havrilesky LJ, Cragun JM, Calingaert B, et al. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol. 2005; 99(3): 689–695.
  13. Akbayir O, Corbacioglu A, Goksedef BP, et al. The novel criteria for predicting pelvic lymph node metastasis in endometrioid adenocarcinoma of endometrium. Gynecol Oncol. 2012; 125(2): 400–403.
  14. Zhang C, Wang C, Feng W. Clinicopathological risk factors for pelvic lymph node metastasis in clinical early-stage endometrioid endometrial adenocarcinoma. Int J Gynecol Cancer. 2012; 22(8): 1373–1377.
  15. Quinn M, Benedet J, Odicino F, et al. Carcinoma of the uterine cervix. FIGO 26th annual report on the results on treatment in gynaecological cancer. Int Gynaecol Obstet. 2006; 95: S43–S103.
  16. Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008; 198(2): 218.e1–218.e6.
  17. Dane C, Bakir S. The effect of myometrial invasion on prognostic factors and survival analysis in endometrial carcinoma. Afr Health Sci. 2019; 19(4): 3235–3241.
  18. Kadar N, Malfetano JH, Homesley HD. Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications for therapy. Obstet Gynecol. 1992; 80(4): 655–659.
  19. Kumar S, Podratz KC, Bakkum-Gamez JN, et al. Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. Gynecol Oncol. 2014; 132(1): 38–43.
  20. Kaku T, Tsuruchi N, Tsukamoto N, et al. Reassessment of myometrial invasion in endometrial carcinoma. Obstet Gynecol. 1994; 84(6): 979–982.
  21. Kitchener H, Swart AMC, Qian Q, et al. ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373(9658): 125–136.
  22. Mariani A, Webb MJ, Rao SK, et al. Significance of pathologic patterns of pelvic lymph node metastases in endometrial cancer. Gynecol Oncol. 2001; 80(2): 113–120.
  23. Panici PB, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. JNCI Journal of the National Cancer Institute. 2008; 100(23): 1707–1716.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl